close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

8.250 -1.520 (-15.56%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Puma Biotechnology (PBYI) Q3 2026 Earnings Call Transcript ↗
International shipments kept third-quarter revenue steady despite softer domestic NERLYNX sales. 
Via The Motley Fool
Topics Earnings
News headline image
Puma Biotechnology Q3 Earnings Call Highlights ↗
Puma Biotechnology (NASDAQ:PBYI) reported third-quarter 2026 revenue of $55.1 million and raised its full-year net income forecast, even as it lowered its outlook for royalties and narrowed its sales... 
Via MarketBeat
Topics Earnings
Puma Biotechnology (NASDAQ:PBYI) Q3 Earnings: EPS Beat, Revenue Miss, and Gross-to-Net Pressure ↗
Via Chartmill
News headline image
Puma Biotechnology Reports Third Quarter 2026 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology (NASDAQ:PBYI) Beats Q2 Estimates, but Soft Q3 Guidance Tempers Reaction ↗
Via Chartmill
PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) Beats Q1 Estimates, Raises Full-Year Guidance ↗
Via Chartmill
Puma Biotechnology (NASDAQ:PBYI) Beats Q4 Estimates, Guides for Profitable 2026 ↗
Via Chartmill
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript ↗
NERLYNX demand surged 12% year over year as Puma raised full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Puma Biotechnology Q2 Earnings Call Highlights ↗
Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The... 
Via MarketBeat
Topics Earnings
News headline image
Puma Biotechnology Reports Second Quarter 2026 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma (PBYI) Q1 2026 Earnings Call Transcript ↗
Puma (PBYI) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Puma Biotechnology Q1 Earnings Call Highlights ↗
Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million,... 
Via MarketBeat
Topics Earnings
News headline image
Puma Biotechnology Reports First Quarter 2026 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. 
Via The Motley Fool
News headline image
Puma Biotech (PBYI) Earnings Call Transcript ↗
Puma Biotech (PBYI) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.